Syndax Begin Period Cash Flow vs Change In Cash Analysis
SNDX Stock | USD 14.94 0.62 3.98% |
Syndax Pharmaceuticals financial indicator trend analysis is much more than just breaking down Syndax Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Syndax Pharmaceuticals is a good investment. Please check the relationship between Syndax Pharmaceuticals Begin Period Cash Flow and its Change In Cash accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
Begin Period Cash Flow vs Change In Cash
Begin Period Cash Flow vs Change In Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Syndax Pharmaceuticals Begin Period Cash Flow account and Change In Cash. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Syndax Pharmaceuticals' Begin Period Cash Flow and Change In Cash is -0.15. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Syndax Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Syndax Pharmaceuticals' Begin Period Cash Flow and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Syndax Pharmaceuticals are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Begin Period Cash Flow i.e., Syndax Pharmaceuticals' Begin Period Cash Flow and Change In Cash go up and down completely randomly.
Correlation Coefficient | -0.15 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Change In Cash
Most indicators from Syndax Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Syndax Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.At this time, Syndax Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.3 B in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 137.9 M in 2024.
Syndax Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Syndax Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Syndax Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 63.5M | 300.6M | 449.7M | 497.2M | 612.9M | 643.5M | |
Other Current Liab | 10.2M | 11.2M | 14.7M | 24.3M | 47.1M | 49.4M | |
Total Current Liabilities | 18.4M | 18.9M | 20.7M | 29.1M | 58.1M | 61.0M | |
Total Stockholder Equity | 31.6M | 252.2M | 408.4M | 467.4M | 554.2M | 581.9M | |
Property Plant And Equipment Net | 997K | 482K | 1.3M | 1.1M | 1.5M | 1.6M | |
Net Debt | (23.7M) | (94.7M) | (201.0M) | (73.2M) | (293.8M) | (279.1M) | |
Retained Earnings | (495.5M) | (568.6M) | (543.7M) | (693.0M) | (902.4M) | (857.3M) | |
Accounts Payable | 6.2M | 3.5M | 5.7M | 4.4M | 10.0M | 10.5M | |
Cash | 24.6M | 115.2M | 222.0M | 74.4M | 295.4M | 310.2M | |
Non Current Assets Total | 1.2M | 1.7M | 1.3M | 16.0M | 32.0M | 33.6M | |
Non Currrent Assets Other | 82K | 1.2M | 983K | 9.4M | 680K | 646K | |
Cash And Short Term Investments | 59.8M | 293.1M | 439.9M | 481.3M | 577.6M | 606.5M | |
Common Stock Shares Outstanding | 30.5M | 41.3M | 53.6M | 60.8M | 70.4M | 38.8M | |
Short Term Investments | 35.2M | 177.8M | 218.0M | 410.0M | 282.2M | 296.3M | |
Liabilities And Stockholders Equity | 63.5M | 300.6M | 449.7M | 497.2M | 612.9M | 643.5M | |
Non Current Liabilities Total | 13.6M | 29.6M | 20.6M | 722K | 588K | 558.6K | |
Other Current Assets | 763K | 5.6M | 7.9M | 9.9M | 2.1M | 2.7M | |
Other Stockholder Equity | 527.1M | 820.8M | 952.0M | 1.2B | 1.5B | 1.5B | |
Total Liab | 31.9M | 48.4M | 41.3M | 29.8M | 58.7M | 34.5M | |
Property Plant And Equipment Gross | 997K | 482K | 1.7M | 1.5M | 1.9M | 2.0M | |
Total Current Assets | 62.3M | 298.9M | 448.4M | 481.3M | 580.9M | 609.9M | |
Accumulated Other Comprehensive Income | (310K) | (4K) | 45K | (806K) | 218K | 228.9K | |
Short Term Debt | 478K | 2.6M | 362K | 439K | 1.0M | 994.7K | |
Common Stock | 3K | 5K | 6K | 7K | 8K | 8.4K | |
Other Liab | 17.1M | 14.8M | 13.1M | 11.6M | 13.4M | 14.2M | |
Net Tangible Assets | 31.6M | 252.2M | 408.4M | 467.4M | 537.6M | 564.4M | |
Other Assets | 219K | 0.0 | 1.6M | 922K | 829.8K | 472.8K | |
Net Receivables | 116K | 175K | 429K | 4.1M | 1.2M | 795.6K | |
Inventory | 1.7M | 5.3M | 7.7M | (4.3M) | 2.0M | 1.6M | |
Property Plant Equipment | 997K | 192K | 278K | 1.1M | 1.2M | 1.3M | |
Retained Earnings Total Equity | (439.4M) | (495.5M) | (568.6M) | (543.7M) | (489.3M) | (513.8M) | |
Capital Surpluse | 492.5M | 527.1M | 820.8M | 952.0M | 1.1B | 669.6M | |
Non Current Liabilities Other | 136K | 5K | 11.7M | 711K | 817.7K | 776.8K | |
Net Invested Capital | 31.6M | 272.3M | 428.3M | 467.4M | 554.2M | 300.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.